GRZAN Pakistan Medical Device Registration Services

1. Key takeaways

GRZAN delivers full-process services for medical device registration in Pakistan. The service chain maps strictly onto the rule requirements: classification determination (Class A/B/C/D), institutional licence processing (import or local production), enlistment or registration filing (Form-6A / Form-7A), preparation of the technical documentation in English, arrangement of the local authorised representative, coordination of the import licence and PSW customs clearance, and post-market vigilance together with five-year renewal management. Each stage in the chain exists because a specific rule creates the corresponding requirement, so the sequence is not a matter of preference but of regulatory logic: nothing downstream can start before its upstream prerequisite is satisfied. A client engaging at any single stage still benefits from the same discipline, because the deliverables at every stage are defined by the same rule set that will later be used to judge them. The chain also gives the client a shared vocabulary: when a stage is delayed, the conversation can point to the specific prerequisite that is missing, rather than to a vague sense that something is slow.

2. Legal basis

The table below links each service stage to the rule node that governs it, so the client can see at a glance which provision stands behind each piece of work and which document or portal the provision names.

3. Expert insights

Insight one: the three hard thresholds of a Pakistan project. The institutional licence must come first (Rule 14(1)(b)); all applications run online only (from 21 July 2025); and the certificate is renewed every five years (Rule 15(4)). These three are the skeleton of the schedule. Everything else — document preparation, legalisation, fee planning, customs coordination — hangs off one or more of them, and a project plan that treats them as details rather than as the load-bearing structure will misjudge its own critical path. The licence threshold in particular is a sequencing fact, not a formality: no product filing exists without the importer behind it, so the licence workstream must start before the dossier workstream, not after. The online-only threshold, likewise, eliminates any fallback plan a team may be carrying in its head about couriering a paper set.

Insight two: reference-country approval is the key variable for speed. Rule 15(2) lists the regulatory approvals of 17 countries and regions, together with WHO prequalification and CE marking by notified bodies listed in the NANDO database, as bases for reliance and exemption. Whether the product already holds one of these determines whether the review runs on the simplified route or the standard route. This makes the reference-approval inventory the single most valuable diagnostic exercise at project start: it costs a few days of document gathering and can save months of review time. Where no listed approval exists, the standard route remains available but the schedule must absorb it honestly rather than optimistically. The inventory should be refreshed whenever a new approval is obtained elsewhere, because a certificate earned in one listed market can quietly convert a pending Pakistani filing onto the faster route.

Insight three: the Hague Convention exception requires separate verification. Pakistan has acceded to the 1961 Hague Convention through the Apostille Ordinance, 2024 (Ordinance No. I of 2024, gazetted 2024-01-26) and the Apostille Act, 2024 (Act No. XXI of 2024, approved on 2024-09-06), but 8 countries have raised objections. The reference-country list and the objection list overlap, so the certification chain must be confirmed country by country before it is relied upon. An apostille that is valid for one reference country may be useless for another, and the consequence of assuming otherwise is a document rejected at the filing stage after weeks of notarial work. The dual 2024 instruments — ordinance followed by act — also mean the legal basis must be cited in its current, act-based form rather than from older guidance that still references the ordinance.

4. Practical recommendations

GRZAN recommends that clients advance their Pakistan projects in three steps. Step one is classification and qualification diagnosis: determine the class, confirm the reference-country approval status, and take stock of the institutional licence requirements. Step two is the certification chain and document preparation: notarisation and consular legalisation of the FSC, notarisation of the authorisation letter, and preparation of the technical documentation in English. Step three is portal filing and follow-up management: online submission, response to deficiencies, and, once the certificate is obtained, scheduling of import and renewal plans. Each step has clearly defined deliverables, so the client can judge progress at any time. The three steps also map naturally onto three different kinds of risk — regulatory classification risk, document authenticity risk and process risk — which means the client can hold each step to its own standard of completion instead of waiting for one undifferentiated finish line.

5. Verification checklist

• □ Product classification has been determined (Class A / B / C / D)
• □ The import institutional licence has been obtained, or its processing has been started
• □ Reference-country approval evidence has been inventoried (the 17-country list / WHO PQ / NANDO CE)
• □ The certification chain has been planned (including the check of Hague Convention objecting states)
• □ A filing account has been established through the e-Services portal
• □ Post-market vigilance and the five-year renewal management schedule have been arranged

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Pakistan. Our team prepares dossiers to DRAP expectations, manages eCTD-format submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com